The store will not work correctly in the case when cookies are disabled.
We use cookies to make your experience better.To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies.Learn more.
Chemically defined, animal component-free medium for suspension HEK293 cells in perfusion mode.
BalanCD HEK293 Perfusion A is specifically optimized for high cell density (HCD), intensified processes, and perfusion cultures for AAV and LV production.
Support both steady-state and intensified perfusion workflows for process flexibility
Achieve high cell densities with minimal byproduct accumulation for improved viral vector output
Reach cell specific perfusion rate (CSPR) of 25 pL/cell/day to maximize efficiency and reduce operational costs
Improve process efficiency and reduce costs by achieving higher yields, product quality, and supporting stable, inducible vector systems
Process Intensification in HEK293 Perfusion Culture
Figure 1. BalanCD HEK293 Perfusion A supports high cell density (HCD) process intensification through perfusion culture. Maximum viable cell density (VCD) in suspension HEK293 cells cultured in 5 L bioreactor equipped with ATF (alternating tangential flow) device, where culture was maintained at a constant CSPR of 25 pL/cell/day. VCD increases progressively up to the peak VCD of ~1.18 x 108 cells/mL at Day 9 post-inoculation.
HCD Transfection and Induction for AAV Production in Perfusion Culture
Figure 2. HCD transfection for AAV2 production in 5 L bioreactor equipped with ATF device. Suspension HEK293 cells were cultured in BalanCD HEK293 Perfusion A, maintained at a constant CSPR of 25 pL/cell/day and triple-transfected with AAV2 plasmids using PEI. Cell growth continued up to 4.8 x 107 cells/mL with 90% viability at time of harvest (A). AAV2 viral genome (VG) titer was measured daily up to Day 3 post-transfection, reaching 5.0 x 1011 VG/mL (B).
Custom sizes and packaging available upon request.
Contact us for international pricing and custom formulations.
